HEMATOLOGY
Support your early phase hematology program by partnering with a CRO that has relevant nonclinical and clinical expertise, aided by efficacy measures using flow cytometry or coagulation measures, including thromboelastography (TEG) and bioanalytical methods for a number of biomarkers. Hematology encompasses the study of blood and blood-related disorders, including conditions such as anemia, leukemia, lymphoma, and various clotting disorders. Clinical trials in hematology aim to improve our understanding of these conditions and develop new and more effective treatments.
Both our preclinical and clinical facilities perform flow cytometry, including when methods require samples to be analyzed within four hours of collection. We investigate coagulation directly or look for changes in different components of the coagulation cascade. If the focus is on the immune system, we have validated methods for a number of steps in the complement pathway.
Types of Hematology Trials:
- Drug Trials: Investigate the safety and efficacy of new medications for various hematological disorders, including leukemia, lymphoma, myeloma, and clotting disorders.
- Cell Therapy Trials: Assess the effectiveness and safety of cellular therapies, such as hematopoietic stem cell transplantation or gene therapy, for conditions like aplastic anemia, sickle cell disease, or certain types of leukemia.
- Transfusion Medicine Trials: Evaluate new blood products, transfusion strategies, or blood management approaches.
- Prevention Trials: Focus on strategies to prevent the development or recurrence of blood disorders, including studies on anticoagulation, thromboprophylaxis, or genetic screening.
Endpoints:
- Common endpoints in hematology trials include improvements in blood cell counts, reduction in symptoms (e.g., fatigue, bleeding), overall survival, and quality of life measures.